DUBLIN–(BUSINESS WIRE)–The “Pharmaceutical Intermediates Market Forecast to 2028 – COVID-19 Impact and Global Analysis by Type; Applications; Distribution Channel, and Geography” report has been added to ResearchAndMarkets.com’s offering.
The global pharmaceutical intermediates market is expected to reach US$ 37,290.33 million in 2028 from US$ 27,356.70 million in 2020. The market is estimated to grow with a CAGR of 3.95% during 2020-2028.
Countries in Asia Pacific are emerging as attractive outsourcing locations for pharmaceuticals and biopharmaceuticals industries. Low manufacturing and operating costs in China and India are key factors driving the pharmaceutical manufacturing business in the region. Recent growth in the pharmaceutical industry in both these countries indicate a positive outlook for the pharmaceutical intermediates market. As per the India Brand Equity Foundation (IBEF), an initiative of the Ministry of Commerce & Industry of the Government of India, the value of the pharmaceutical industry in India is expected to reach US$ 100 billion by 2025. Moreover, pharmaceuticals export from India was worth US$ 16.3 billion in 2020; these exports include drug formulations, bulk drugs, intermediates, biologicals, and herbal products.
Flourishing domestic pharmaceutical market in APAC and increasing number of pipeline drugs are further opening new avenues for the contract manufacturers as well as generic drug manufacturing in the region. As per IBEF, India’s domestic pharmaceutical market business revenue reached US$ 20.03 billion (INR 1.4 lakh crore) in 2019, with a year-on-year (y-o-y) increase of 9.8% from US$ 18.12 billion (INR 129,015 crore) in 2018. Additionally, to meet the growing demand, many contract-based organizations are expanding their manufacturing capabilities, further boosting the growth of the market.
The pharmaceutical intermediates market, by type, is segmented into GMP, and non GMP. The GMP segment held the largest share of the market in 2020, whereas the same segment is anticipated to register the highest CAGR of 4.4% in the market during the forecast period.
In terms of application, the pharmaceutical intermediates market is segmented antibiotics, antipyretic analgesics, vitamins, and others. The antibiotics segment held the largest share of the market in 2020, also, this segment is anticipated to register the highest CAGR of 4.9% in the market during the forecast period.
The pharmaceutical intermediates market, by distribution channel, is segmented into distributor, and direct sales. The direct sales segment held the largest share of the market in 2020, and distributor segment is estimated to register the highest CAGR of 4.2% in the market during the forecast period.
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the pharmaceutical intermediates market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the global pharmaceutical intermediates market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution
Market Dynamics
Drivers
- Rising Prevalence of Chronic Diseases and Infectious Diseases
- Escalating R&D Investments by Pharmaceutical Companies
Restraints
- High Cost of Manufacturing
Opportunities
- Emerging Markets
Future Trends
- Increasing Adoption of AI-based Tools for Drug Discovery
Companies Mentioned
- Pfizer, Inc
- Dishman Group
- Dextra Laboratories Limited
- Sanofi Winthrop Industries S.A.
- Vertellus Holdings LLC
- BASF SE
- Lianhetech
- Codexis
- Midas Pharma GmbH
- Chiracon GmbH
For more information about this report visit https://www.researchandmarkets.com/r/9jiwpe.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900